Intensive blood pressure control proves safe and effective across all diastolic levels: Evidence from China

Chinese scientists have found compelling evidence that intensive blood pressure (BP) control — targeting below 130/80 mm Hg — is both safe and effective for hypertensive patients regardless of their baseline diastolic blood pressure (DBP). Published in Heart, the study is a secondary analysis of the China Rural Hypertension Control Project, one of the largest real-world intervention trials of its kind.

For decades, the so-called “J-curve” phenomenon has led many clinicians to worry that reducing BP too aggressively in patients with low DBP could increase cardiovascular risk. Drawing on data from 33,288 participants across four DBP quartiles, the analysis shows that intensive treatment reduced cardiovascular events uniformly across all groups — with hazard ratios ranging from 0.59 to 0.69 — and did not increase the risk of injurious falls, syncope, or adverse kidney outcomes. The only notable side effect was a higher incidence of hypotension, which was manageable.

The study is significant not only for its sheer scale but for its design: it deployed non-physician providers to deliver the intervention, demonstrating a model that could be replicated in resource-limited settings worldwide. As hypertension remains the leading modifiable risk factor for premature death globally, these findings from China offer a practical, evidence-based path to more aggressive — and more equitable — cardiovascular prevention.

Why it matters:
The results directly challenge the clinical caution that has constrained intensive BP management for low-DBP patients, potentially unlocking more aggressive treatment protocols worldwide. For drug developers and health systems, the study also validates the use of task-shifting models — where trained non-physicians lead care — as a scalable strategy for managing chronic disease in both developed and developing markets.

Source →